1. Home
  2. ICG vs ANVS Comparison

ICG vs ANVS Comparison

Compare ICG & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ICG

Intchains Group Limited

HOLD

Current Price

$0.90

Market Cap

52.6M

Sector

Technology

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.19

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICG
ANVS
Founded
2017
2008
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.6M
50.4M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
ICG
ANVS
Price
$0.90
$1.19
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$2.00
★ $10.50
AVG Volume (30 Days)
43.5K
★ 1.1M
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$109.44
N/A
P/E Ratio
$6.80
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$1.04
52 Week High
$2.28
$5.50

Technical Indicators

Market Signals
Indicator
ICG
ANVS
Relative Strength Index (RSI) 52.69 38.01
Support Level $0.81 $1.04
Resistance Level $1.04 $2.43
Average True Range (ATR) 0.11 0.09
MACD -0.01 0.02
Stochastic Oscillator 65.35 38.46

Price Performance

Historical Comparison
ICG
ANVS

About ICG Intchains Group Limited

Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: